Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention

Circulation. 2003 Nov 11;108(19):e138; author reply e138. doi: 10.1161/01.CIR.0000099921.71299.D9.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Abciximab
  • Acute Disease
  • Aged
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Anticoagulants / therapeutic use
  • Cohort Studies
  • Combined Modality Therapy
  • Coronary Circulation / drug effects*
  • Coronary Disease / drug therapy*
  • Coronary Disease / therapy
  • Coronary Vessels / physiopathology*
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab